ArticleJournal of thoracic disease2025
Delay in lung volume reduction surgery due to the COVID-19 pandemic: impact on patient performance and mortality.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe chronic obstructive pulmonary disease (COPD) naturally progresses over time and is associated with increased mortality. During the coronavirus disease 2019 (COVID-19) pandemic, many surgical procedures were postponed, but the full impact of these delays remains unclear. Our aim was to evaluate the consequences of delayed lung volume reduction surgery (LVRS) treatment. Methods: This study was conducted as a retrospective observational study. Patients who had LVRS postponed six months or more due to the COVID-19 pandemic at a national university centre were included. Data were obtained from an institutional database. Patients were re-evaluated before surgery using lung function tests, a 6-minute walking test (6MWT), and blood gas analysis. Increased symptoms, mortality, and infections were recorded. All surviving patients were reassessed for treatment indication in a multidisciplinary team (MDT) meeting. Results: A total of 67 patients had their scheduled LVRS treatment postponed due to the pandemic. Of these 16% were infected with COVID-19. Four patients (6%) died before secondary evaluation. Mean time from outpatient clinic referral to surgery date was 398 (±161) days. Forced expiratory volume in one second (FEV1) significantly decreased by 0.1 L (P<0.001), while diffusion capacity of the lung for carbon monoxide (DLCO) remained unchanged. Performance in the 6MWT worsened by 29.9 m (P<0.001), and oxygen saturation decreased by 1.3% (P=0.046). Symptom worsening was experienced in 39% of patients. Clinical deterioration rendered 5% of patients unfit for surgery, while 86% remained fit for surgery. No patients were excluded due to COVID-19 infection. Conclusions: The delay of LVRS due to the COVID-19 pandemic led to a decrease in lung function, 6MWT performance, and oxygen saturation. Although the majority of patients remained fit for surgery, the postponement resulted in cancellation of procedures due to clinical deterioration and contributed to waiting list mortality. This patient group is vulnerable to further deterioration over time and timely treatment should be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.